Analyst Ratings For Hikma Pharmaceuticals Plc (LON:HIK)
Today, Barclays reiterated its Underweight rating on Hikma Pharmaceuticals Plc (LON:HIK) with a price target of GBX 1,400.
There are 6 Hold Ratings, 1 Sell Ratings, 1 Buy Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Hikma Pharmaceuticals Plc (LON:HIK) is Hold with a consensus target price of GBX 1,388.38 per share, a potential .
Some recent analyst ratings include
- 8/24/2018-Hikma Pharmaceuticals Plc (LON:HIK) had its Underweight rating reiterated by Barclays with a GBX 1,400 price target
- 8/21/2018-Hikma Pharmaceuticals Plc (LON:HIK) had its Neutral rating reiterated by JPMorgan Chase & Co. with a GBX 1,050 price target
- 8/15/2018-Hikma Pharmaceuticals Plc (LON:HIK) had its Hold rating reiterated by Numis Securities
- 5/18/2018-Hikma Pharmaceuticals Plc (LON:HIK) had its Hold rating reiterated by Jefferies Financial Group with a GBX 997 price target
About Hikma Pharmaceuticals Plc (LON:HIK)
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Recent Trading Activity for Hikma Pharmaceuticals Plc (LON:HIK)
Shares of Hikma Pharmaceuticals Plc closed the previous trading session at 1,899.50 up +21.50 1.14% with 10.23 shares trading hands.